BOSTON - Pyxis Oncology, Inc. (NASDAQ:PYXS) announced Tuesday that Thomas Civik has been appointed Interim Chief Executive Officer, effective immediately. Civik, who has served on the company’s board ...
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a ...
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a ...
MOL PLUS has decided to invest in Pyxis Maritime, a Singapore-based developer of electric vessels and operator of electric boat charging stations, as part of efforts to promote the commercialization ...
Pyxis secured S$13 million in the first close of its S$18 million growth funding round, reflecting strong investor confidence in its vessel technology, commercial traction, and regional growth ...
Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell ...
Shares of Pyxis Oncology dropped after the pharmaceutical company said data from its trials on a treatment for a form of head and neck cancer showed a high incidence of adverse effects. The stock fell ...
Pyxis Oncology ( (PYXS)) has provided an announcement. On December 18, 2025, Pyxis Oncology reported positive preliminary Phase 1 data for its first-in-concept antibody-drug conjugate MICVO in ...
Investing.com - Pyxis Oncology Inc. (NASDAQ:PYXS) shares declined after RBC Capital lowered its price target to $5.00 from $8.00 while maintaining an Outperform rating. The adjustment follows Pyxis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results